These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 4034580)
1. Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic cancer. Santen RJ; English H; Rohner T; Drago J; Lipton A; Harvey H; Simmonds M; Boucher A; Glode LM; Wettlaufer J Prog Clin Biol Res; 1985; 185A():359-71. PubMed ID: 4034580 [No Abstract] [Full Text] [Related]
2. New principles in the management of metastatic prostatic cancer. Isaacs JT Prog Clin Biol Res; 1985; 185A():383-405. PubMed ID: 4034581 [No Abstract] [Full Text] [Related]
3. [New hormonal treatments of metastatic prostatic cancer. Review of the literature]. Dubost JJ; Sauvezie B; Ristori JM; Thevenet JP; Rampon S Rev Rhum Mal Osteoartic; 1985 Oct; 52(10):577-85. PubMed ID: 3909364 [No Abstract] [Full Text] [Related]
4. A rat prostatic adenocarcinoma as a model for the human disease. Müntzing J; Kirdani RY; Murphy GP; Sandberg AA Invest Urol; 1979 Jul; 17(1):37-41. PubMed ID: 447485 [TBL] [Abstract][Full Text] [Related]
5. Innovative approaches to the hormonal treatment of advanced prostate cancer. Trachtenberg J Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of estrogen-resistant forms of cancer of the prostate]. Marinbakh EB; Ar'e VM Urol Nefrol (Mosk); 1974; 39(4):68-74. PubMed ID: 4606039 [No Abstract] [Full Text] [Related]
8. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Ellis WJ; Isaacs JT Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963 [TBL] [Abstract][Full Text] [Related]
9. Management of newly diagnosed metastatic carcinoma of the prostate. Elder JS; Catalona WJ Urol Clin North Am; 1984 May; 11(2):283-95. PubMed ID: 6428022 [TBL] [Abstract][Full Text] [Related]
10. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749 [TBL] [Abstract][Full Text] [Related]
12. New agents in metastatic prostate cancer. Fizazi K; Massard C Eur J Cancer; 2009 Sep; 45 Suppl 1():379-80. PubMed ID: 19775638 [No Abstract] [Full Text] [Related]
13. [Cancer of the prostate: what treatment for what stage?]. Vanden Bossche M Rev Med Brux; 1999 Sep; 20(4):A206-11. PubMed ID: 10523894 [TBL] [Abstract][Full Text] [Related]
14. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?]. Matveev BP; Bukharkin BV Urologiia; 2003; (6):6-10. PubMed ID: 14708235 [TBL] [Abstract][Full Text] [Related]